Navigation Links
Arsenal Capital Partners übernimmt führendes Unternehmen für modellbasierte Arzneimittelentwicklung Certara
Date:12/20/2013

biopharmazeutische Industrie, die ihre aktuellen Praktiken maßgeblich verändern werden. Technologiegesteuerte Informatikmodelle werden nicht nur zu kostensparenderer Arzneimittelentwicklung führen, sondern auch als Grundlage für die Bereitstellung personalisierter Medizin und klinischer Versorgung dienen. Wir haben vor, auf die bestehenden Softwareentwicklungsprodukte und Beratungsdienstleistungen von Certara aufzubauen, um das Unternehmen zu einem noch stärkeren, vielseitigeren Partner für seine Pharma- und Biotech-Kunden zu machen und letztendlich die Vision von Arsenal im Hinblick auf personalisierte Medizin umzusetzen."

Die Übernahme von Certara durch Arsenal folgt auf die Übernahme und Konsolidierung in die WIRB-Copernicus Group (WCG) des Western Institutional Review Board (WIRB), der Copernicus Group IRB und IRBNet von 2012. Die Übernahme von Certara erweitert das Dienstleistungsangebot, das durch die Portfoliounternehmen für Pharma- und Biotech-Unternehmen sowie Auftragsforschungsorganisationen bereitgestellt werden kann. WCG bietet unabhängige IRB-Dienstleistungen und verfügt über gesetzlich vorgeschriebene IRB-Gremien.

Informationen zu Arsenal Capital Partners
Arsenal Capital Partners ist ein führendes Private-Equity-Unternehmen mit Sitz in New York, das in mittelständische Gesundheits- und Spezialindustrieunternehmen investiert. Arsenal investiert in Branchen, zu welchen das Unternehmen über wesentliche Vorkenntnisse und Erfahrung verfügt. Arsenal ist an Unternehmen interessiert, die das Potential für zusätzliche Wertschöpfung bieten, die durch eine enge Zusammenarbeit mit dem Management zur Beschleunigung des Wachstums und der optimalen Nutzung der Kompetenzen zur Verbesserung der Betriebsprozesse des Unternehmens erreicht wird. Arsenal verzeichnet aktuell ein zugesichertes Beteiligungskapital i. H. v. 1,7 Mrd. U
'/>"/>

SOURCE Arsenal Capital Partners
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arsenal Capital Partners verwerft Certara, leider in geneesmiddelontwikkeling op basis van modellen
2. Arsenal Capital Partners Acquires Leading Model-Based Drug Development Company Certara
3. Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
4. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
5. TVM Capital Group Announces Two-pronged Global Investment Strategy with Renewed MENA Focus
6. Foundation Venture Capital Group Portfolio Company Identifies FRY Gene As Breast Cancer Susceptibility Suppressor
7. S&P Capital IQ to Share Its Views on the Biotech Bull Market During the Next "ETF Analyst Hour"
8. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
9. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
10. GW Pharmaceuticals to Present at the 2013 Aegis Capital Healthcare Conference
11. Capitalizing on Opportunities in Cord Blood Industry Growth (2013 Version)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 1, 2015 R-Japan Co.,Ltd. obtained the license of ... Regenerative Medicine from the Ministry of Health, Labour and Welfare ... The fact that R- Japan ... auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on May ... to provide stem cell manufacturing service to medical institutions. As ...
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... on developing therapeutics that address unmet medical needs ... George Elston will present at the Cantor ... July 8, 2015Time: , 4:45 PM EDTLocation: , ... & archive): , www.juniperpharma.com, under  ,Investor, ...
(Date:6/30/2015)... ... June 30, 2015 , ... The maximum number of shares proposed to be ... (including shares of unvested restricted stock). On June 29, 2015, the last trading day ... shares reported on the OTCBB was $2.29 per share. , The tender offer will ...
(Date:6/30/2015)... NEW YORK , June 30, 2015  The Dr. ... is now offering a full suite of new ... who,ve had a biopsy, for diagnosing prostate cancer. ... a range of genetic tests for assessing the risk and ... "We,re very excited to now offer these ...
Breaking Biology Technology:R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 2Cryo-Cell Commences Tender Offer to Purchase its Common Stock, Up to 750,000 Shares at $3.25 per Share 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5
... Dendreon Corporation today announced that Chief Executive Officer, Mitchell ... & Young Entrepreneur Of The Year (R) 2009 ... & Young LLP, the awards program recognizes entrepreneurs who ... performance and personal commitment to their businesses and communities. ...
... /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS;,Nasdaq: PXSL ) ... Food and Drug Administration (FDA) that the New Drug ... been accepted for,standard review. The FDA will advise ... Pharmaxis is seeking approval for ...
... DIEGO, May 13 Dr. Feng Lin, Director of ... BMSN) and Entest BioMedical Inc., today stated that he ... injury" (TBI) using autologous "adipose-derived" stem cells represents a ... both Bio-Matrix and Entest BioMedical are now studying the ...
Cached Biology Technology:Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest 2U.S. FDA Accepts Aridol(TM) New Drug Application for Review 2'Adipose-derived' Stem Cells Could Help Traumatic Brain Injury Patients, Says Bio-Matrix Scientific Group's, Entest BioMedical Inc. Researcher 2
(Date:6/16/2015)... 2015 /CNW Telbec/ - handyem Inc. and FlowMetric ... incorporation of handyem,s HPC-150 portable flow cytometer within ... This unprecedented model of mobile laboratory platform is ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue ...
(Date:6/15/2015)... , June 15, 2015 A ... from Telstra reveals the majority of US consumers using mobile ... via biometrics, such as fingerprint and voiceprint, instead of having ... According to Telstra,s " Mobile Identity   -   ... report, with smartphones now the primary channel used by ...
(Date:6/9/2015)... June 9, 2015   MedNet Solutions , an ... spectrum of clinical research, will be providing demonstrations of ... at the 2015 Drug Information Association (DIA) Annual Meeting ... 15-17.  These presentations will include previews of many exciting ... the upcoming iMedNet 2015 Feature 1 Release. ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... avoid cancer of the kidneys, a new major study from ... kinds of fatty fish a few times a month would ... the end of the 1980s, 90,000 Swedish women were sent ... mammography scan. Now, with the help of another questionnaire a ...
... dramatic increase in testicular cancer, now the most ... the focus of a five-year, $5.5 million National ... researcher Tongzhang Zheng. , Testicular cancer is increasing ... important information on possible environmental, genetic and other ...
... have discovered a new, more accurate, method of mapping ... could lead to more effective treatments and prevention of ... Duncan Maskell at the Centre for Veterinary Science, and ... with observational data to predict the spread of individual ...
Cached Biology News:Researchers map spread of pathogens in the human body 2
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Rabbit polyclonal to FANCG ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSRQTTSVGSSC, corresponding to amino acids 1 - 12 of Human FANCG. Entrez GeneID: 2189 Swis...
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6...
...
Biology Products: